Research Funding vs Startup Funding: Understanding the journey from Research to Commercialization

Research funding and startup funding serve different purposes. Understand TRLs, funding sources, commercialization pathways, and how research moves from the lab to the market.

After spending 18 years in the startup ecosystem, I have had the opportunity to interact with thousands of startups, entrepreneurs, researchers, innovators and institutions. Over the years, I have developed a particular soft corner for deep tech and research-led businesses. There is something fascinating about seeing years of scientific inquiry, experimentation and technological development eventually solve a real-world problem.

As India’s startup ecosystem matures, we are seeing much greater interest in deep tech, indigenous technology and the commercialisation of academic and institutional research. Researchers are exploring entrepreneurship. Incubators are working with universities. Government programmes are supporting innovation. Corporates are looking towards research institutions for technologies that can solve industry problems. Private capital is also becoming increasingly interested in research-led opportunities. This is an encouraging development. But it is also creating a confusion that I encounter surprisingly often.

Research funding and startup funding are being treated as though they are interchangeable. They are two different beasts altogether.

The distinction matters because the purpose of the capital is different. So are the sources, milestones, timelines and capabilities required.

A prototype does not necessarily mean you have a startup

Imagine a research team working on a new material that can dramatically improve battery performance. After several years of research, the team successfully demonstrates the underlying scientific principle. They produce the material in a laboratory, test it under controlled conditions and perhaps even create a prototype battery. There is clearly something valuable here. But are they ready to build a business around it? Perhaps. Perhaps not yet.

The material may still need to demonstrate stability across thousands of charging cycles. The manufacturing process that works for a few grams in a laboratory may fail when production moves to kilograms or tonnes. There may be safety questions, certification requirements and unresolved production economics. The technology may perform beautifully in controlled laboratory conditions and behave differently inside a commercially manufactured battery.

These are technological uncertainties, and they need to be resolved before commercial success can even become the primary question.

This is where Technology Readiness Levels, commonly referred to as TRLs, become useful. The TRL framework gives us a way to think about the progression of technology from basic scientific principles through experimental validation, prototype development and demonstration in relevant environments, eventually reaching a technology proven in operational use.

The journey from TRL 1 to TRL 9 can be enormous. Somewhere during that journey, an important transition occurs. The central question gradually moves from Can we make this technology work? to Can we create commercial value from it?

Understanding where you are in that transition is essential before deciding what kind of funding you need.

Research Funding has its own Ecosystem

Startup funding receives enormous public attention. Funding announcements make headlines. Valuations get discussed. Founders talk about fundraising. Incubators conduct investor demo days. As a result, the language of startup funding often becomes the default whenever somebody needs money to develop an innovation. Research has its own funding ecosystem.

Government grants, academic research programmes, university funds, specialised research institutions, scientific missions, private research foundations, corporate R&D programmes, industry-sponsored research, innovation programmes and sector-specific funds can all finance different parts of the research journey.

Support does not always have to arrive purely as money either. Researchers may collaborate with institutions or companies that provide laboratories, testing facilities, equipment, technical expertise, datasets, manufacturing infrastructure or access to specialised talent. These resources can sometimes be as valuable as capital itself.

The landscape also varies significantly by sector. Biotechnology has one ecosystem. Defence technologies have another. Space technology, advanced materials, medical devices, semiconductors, clean energy, climate technology and advanced manufacturing may each involve specialised institutions, grants, programmes and industry partnerships.

So if a technology still requires substantial scientific validation, experimentation, engineering development or technical de-risking, the immediate question should not automatically be Which startup funder should I approach? A better question is What funding and collaboration pathway can help this technology reach commercial readiness?

That small change in the question can completely change the roadmap.

What exactly is the money supposed to achieve?

Perhaps the simplest way to distinguish research funding from startup funding is to ask what uncertainty the money is supposed to resolve.

Research funding primarily deals with scientific and technological uncertainty. Can the hypothesis be validated? Can the required performance be achieved? Can the prototype operate reliably? Can the results be replicated? Can the technology work outside controlled conditions? Can it move towards commercial readiness?

Startup funding deals increasingly with business uncertainty. Who is the customer? What problem are we solving? How much will customers pay? How will the product be manufactured and distributed? What are the economics? How large is the market? How will customers be acquired? Can the organisation repeatedly sell and deliver the product? Can the business scale?

Put simply…Research funding helps take research towards commercially usable technology. Startup funding helps turn commercially usable technology into a viable business.

There will naturally be overlap. Deep-tech companies can continue conducting serious research long after they start generating revenue. Startup funding can also finance product development and technological improvements. The useful distinction lies in identifying the primary uncertainty the capital is expected to resolve at that stage.

The two forms of Funding also operate on different clocks

Some research can move quickly from concept to application. Other technologies require very long gestation periods. Biotechnology, pharmaceuticals, advanced materials, semiconductor technologies, aerospace systems and certain climate technologies can require years of experimentation, testing, validation and regulatory work before meaningful commercial deployment becomes possible.

A research programme may therefore measure progress through scientific milestones, improved performance, successful trials, prototype validation or movement from one TRL to another. Startup funding operates against a different commercial clock. Once technology reaches sufficient commercial readiness, expectations increasingly shift towards customers, revenues, distribution, margins, repeatability and growth.

This difference explains a common source of frustration. A researcher may legitimately say that another two years of experimentation could dramatically improve the technology. Someone funding the startup may legitimately ask when customers will start paying for it.

Both questions can be reasonable. They belong to different stages of the journey.

TRL 9 Is a technology milestone, not the end of commercialisation

Reaching TRL (Technology Readiness Level) 9 represents an extraordinary journey from scientific idea to technology demonstrated in operational use. But technological maturity and commercial success are different achievements.

Consider a medical device that has reached a high level of technological readiness. It works. Its performance has been demonstrated. Yet an enormous commercial journey may remain. Who manufactures it at scale? What does manufacturing cost? What price will hospitals accept? Who makes the purchasing decision? How long is the procurement cycle? What certifications and approvals are necessary? How will clinicians be trained? Who provides maintenance? What competing technologies already exist? What distribution network is required? These questions belong to commercialisation.

Research proves that something can work. Commercialisation determines how that technology creates value in the real world. And that leads to another important distinction.

Commercialisation does not necessarily mean creating a Startup

We frequently talk about encouraging researchers to become entrepreneurs. There are excellent examples where this works beautifully. A scientist or engineer develops a technology, sees its commercial potential, creates a company and successfully builds a business around it. That should remain one pathway among several.

A brilliant researcher does not automatically have to become a brilliant entrepreneur. The capabilities required can be very different. Researchers investigate, experiment, validate hypotheses and solve difficult scientific or engineering problems. Entrepreneurs build organisations, recruit teams, understand markets, negotiate, sell, manage cash flows, create distribution networks and make decisions under commercial uncertainty. Some people can do both exceptionally well. Many will naturally be stronger in one area.

We should therefore avoid building an ecosystem where researchers feel that the only way to commercialise their work is to become CEO, prepare pitch decks, raise startup funding and build a company themselves. Valuable research can reach the market through licensing, technology transfer, corporate partnerships, industry collaborations, joint ventures, spinouts, strategic acquisitions and startup creation.

Consider a university team that develops an advanced industrial coating capable of dramatically extending the life of heavy machinery components. The researchers may have little interest in creating manufacturing facilities and building a national industrial sales network. An established manufacturer may already possess the factories, customers, distribution and application knowledge required. Licensing the technology could take the innovation to market faster and at far greater scale. In another case, the right solution may be a spinout where researchers continue leading the technology while experienced entrepreneurs build the company.

The objective should be successful commercialisation. The startup is one possible vehicle for achieving it.

We need Researchers, Entrepreneurs and Industry to collaborate

Once we stop expecting the researcher to do everything, the commercialisation model becomes much more interesting.

A researcher may understand the technology at a depth few others can match. An entrepreneur may know how to build the organisation. An industry expert may understand customer applications and procurement. A commercialisation specialist may understand licensing and technology transfer. A university may provide laboratories and intellectual property support. Government or private research funding may finance further validation. Startup funding may later finance the commercial organisation.

Each participant solves a different part of the problem. Imagine researchers developing an advanced agricultural technology. The researchers understand the science. An agricultural company understands farmers and distribution. An entrepreneur understands company building. A government research programme helps finance validation. An agricultural university provides field-testing infrastructure. If a standalone company eventually becomes the best commercialisation vehicle, startup funding can support its market journey.

The researcher can remain deeply involved in the technology without carrying the entire burden of building the company. This collaborative model may prove particularly important for deep tech, where scientific depth and commercial complexity can both be substantial.

A better Research-to-Market capital architecture

Rather than putting everything under one generic label called funding, it is more useful to think of research commercialisation as a sequence.

Scientific Research → Research Funding → Technology Development → Prototype → Validation → Commercial Readiness → Commercialisation

At commercialisation, several pathways can emerge

Licensing, Technology Transfer, Industry Partnership, Corporate Commercialisation, Joint Venture, Spinout and Startup

If a startup is the appropriate vehicle, another journey begins

Startup Funding → Business Validation → Market Entry → Repeatability → Growth

Reality will obviously be more complex. Stages can overlap. Research continues after commercialisation. Customer feedback may send a technology back into development. Regulatory requirements can delay market entry. Industry partners may become involved much earlier. But this framework forces one very useful question What stage are we actually financing?

Where Array Ventures is trying to bridge the gap

This gap between research and commercialisation is an area we are increasingly working on at Array Ventures.

We encounter researchers and research-led teams with genuinely interesting technologies and significant commercial potential. Our starting point is to understand where the technology currently sits in its readiness journey. What has been validated? What scientific and engineering uncertainties remain? What testing is required? What infrastructure is needed? What certification or regulatory requirements exist? What would it take to move the technology towards TRL 9 and commercialisation?

From there, the task is to help assemble the appropriate ecosystem around the research. That can involve identifying funding pathways, connecting institutions and specialised expertise, exploring industry collaborations, assessing applications and commercial opportunities, understanding intellectual property strategy and determining the appropriate route to market.

Sometimes that route will be a startup. In other cases it may involve licensing, technology transfer, a corporate partnership or a spinout with an entrepreneurial team working alongside the researchers.

For us, the larger objective is simple: Help promising research travel the difficult distance between the laboratory and the market.

That distance is where many valuable technologies struggle. Scientific capability alone may not solve the commercial problem. Entrepreneurial enthusiasm cannot substitute for unresolved scientific work. Capital deployed without understanding the stage of development may solve neither. The right combination of research, capital, industry, entrepreneurship and institutional support can.

A four-question Framework before you raise money

For any researcher, institution or research-led team considering funding or commercialisation, I would start with four questions.

1. Where are we on the technology-readiness journey? Be realistic about what has actually been demonstrated. A laboratory prototype, validated prototype, commercially deployable product and TRL 9 technology represent very different stages.
2. What uncertainty does the next tranche of money need to resolve? Identify whether the primary uncertainty is scientific, engineering, regulatory, manufacturing, market or business related. This tells you far more about the capital you need than simply asking how much money you want to raise.
3. What is the right funding source for this stage? Explore grants, academic programmes, government research funds, corporate R&D partnerships, private research funds, sector-specific programmes, industry collaborations and other research mechanisms where appropriate. Explore startup funding when the challenge increasingly becomes building and validating the business.
4. What is the best commercialisation pathway? Do not assume that incorporating a startup is automatically the answer. Evaluate licensing, technology transfer, industry partnerships, joint ventures, spinouts and startup creation. Then decide who should lead the commercial journey. Sometimes it will be the researcher. Sometimes it should be an entrepreneur working alongside the researcher.

These four questions create a simple sequence: Stage → Uncertainty → Funding → Commercialisation Pathway. Answer them in that order.

India needs a stronger bridge between Research and Enterprise

India has tremendous scientific and engineering capability across universities, research institutions, government laboratories, corporations and independent innovators. At the same time, the country has developed a much stronger entrepreneurial ecosystem. The opportunity now is to connect these worlds more effectively.

We need patient research capital capable of supporting long development cycles. We need government, academic, corporate and private participation in research funding. We need stronger technology-transfer mechanisms and greater industry participation. We need entrepreneurs willing to work alongside researchers. We need startup funding at the appropriate stage. And we need to recognise that successful commercialisation can take several forms. Most importantly, we need clarity about what we are trying to fund.

A research project does not become a startup simply because a company has been incorporated around it. A prototype does not automatically become a commercially viable product. A researcher does not automatically have to become an entrepreneur for valuable research to reach society.

Research funding and startup funding are two different beasts. Research commercialisation and startup creation are also different concepts.

Understanding those distinctions can help us build a much stronger bridge between laboratories and markets. Because ultimately, we do not need every research project to become a startup. We need more great research to find its way into the real world.